<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03121235</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-2016-664</org_study_id>
    <nct_id>NCT03121235</nct_id>
  </id_info>
  <brief_title>PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.</brief_title>
  <acronym>AzorMan</acronym>
  <official_title>PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome. A Prospective Multicenter Observational Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A standard treatment protocol for invasive aspergillosis (IA) will be implemented in several
      academic hematology centers in the Netherlands in which a diagnostic test demonstrating azole
      resistance by multiplex real-time polymerase chain reaction will guide the choice of
      appropriate antifungal treatment.

      Objectives:

        1. Improve the outcome of patients infected with azole resistant A. fumigatus by the early
           detection of Resistance Associated Mutations (RAMs) and with this the earlier initiation
           of the most appropriate therapy.

        2. Monitor the prevalence of invasive aspergillosis due to strains carrying the TR34/L98H
           or the TR46/T289A/Y121F resistance associated mutations in the Netherlands.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Invasive aspergillosis (IA) is the most common mould infection in immunocompromised
      haematological patients. A relatively low mortality is observed when diagnosis is made early
      and treatment with voriconazole, the first choice of treatment, is initiated promptly.
      However, azole resistance in Aspergillus fumigatus is increasingly reported in Europe. Fungal
      susceptibility testing is difficult, time consuming and not widely available. Furthermore,
      cultures remain negative in the majority of the patients with IA. AsperGenius®, is a CE
      certified multiplex real-time polymerase chain reaction (PCR) assay that allows for a
      simultaneous detection of the presence of Aspergillus species and identification of the most
      common mutations in the A. fumigatus CYP51A gene conferring resistance. The use of this PCR
      results in faster diagnosis of azole resistance and thus the initiation of appropriate
      therapy at an earlier point in time. A fast diagnosis and correct treatment leads to an
      improved outcome. After extensive discussions and a face-to-face meeting with 7 of the 8 UMC
      in the Netherlands a consensus diagnostic and therapeutic protocol was agreed upon. In this
      protocol, the AsperGenius® PCR will be used for the diagnosis of azole resistance and
      antifungal treatment will be changed if resistance is detected. This protocol is the current
      standard diagnostic and treatment approach at Erasmus MC.

      Haematological patients suspected of having an invasive fungal pulmonary infection undergo
      BAL sampling as standard of care. AsperGenius® PCR on BAL sample allows to make a rapid
      diagnosis of invasive aspergillosis and gives information about azole resistance faster than
      standard time consuming methods like fungal culture and galactomannan measurement. A standard
      treatment protocol based on this new diagnostic tool is in place at Erasmus MC and will be
      implemented in the other study centres. The centres will be asked to send BAL sample of at
      least 1ml, preferably 2ml.

      If RAMs are detected, the treating physician will be advised to switch from voriconazole to 1
      of the following options:

        1. Ambisome 3mg/kg IV

        2. In case of treatment limiting toxicity of Ambisome IV, we suggest the use of an
           echinocandin in combination with posaconazole and aiming at serum Cthrough levels of
           3-4mg/L

        3. Step down therapy from IV therapy as described under 1 and 2 to oral therapy with
           posaconazole is allowed after at least 2 weeks of IV therapy and after a documented
           clinical and or radiological response. Posaconazole serum Cthrough levels of 3-4mg/L
           will be aimed for. Step down to posaconazole will not be done if an A. fumigatus strain
           with an MIC of &gt;0.5 microgram/ml is cultured.

        4. As an alternative to posaconazole step down, IV ambisome 5mg/kg thrice weekly can be
           given as well.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Anticipated">October 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of antifungal treatment failure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of antifungal treatment failure in patients with the presence of RAM detected by the AsperGenius® resistance PCR. This incidence will be compared with a fixed failure rate set at 75%, based on the observed treatment failure in patients treated with voriconazole that were shown to carry azole resistant A. fumigatus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstrate that early detection of azole resistance reduces the overall mortality.</measure>
    <time_frame>6 weeks</time_frame>
    <description>This will be compared with a fixed mortality of 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demonstrate that a step down to oral posaconazole is a reasonable treatment option in patients that have responded to at least 2 weeks of IV antifungal therapy.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Posaconazole step down therapy will be considered effective if &lt;35% of the patients treated with posaconazole oral monotherapy show progression of their invasive aspergillosis after documented response after at least 14 days of IV antifungal therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of antifungal treatment failure in patients with the presence of RAM.</measure>
    <time_frame>24 weeks</time_frame>
    <description>A group that received appropriate antifungal therapy soon will be compared with a group that received treatment late.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Aspergillosis, Invasive Pulmonary</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PCR based detection of azole resistance in A. fumigatus</intervention_name>
    <description>Diagnosis and treatment of IA will be based on the results of a standardized diagnosis and treatment protocol that includes the use of the AsperGenius® PCR.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Broncho-alveolar lavage specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an underlying haematological disease (AML, CLL, CML, stem cell transplant
        etc.) aged 18 years and older are eligible if they are presenting with a new pulmonary
        infiltrate on chest CT-scan suspicious for invasive fungal infection and are planned to
        undergo or have undergone a bronchoscopic alveolar lavage (BAL).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with underlying hematological disease

          -  Patient will undergo/underwent BAL sampling for suspected invasive fungal infection

          -  BAL samples should be submitted to the local microbiology lab for fungal culture and
             for galactomannan detection.

          -  The treating physician is planning to start voriconazole, isavuconazole or
             posaconazole after the BAL has been sampled while waiting for the culture or PCR
             results of the BAL sample or has already started voriconazole or posaconazole before
             BAL sampling.

        Exclusion Criteria:

          -  A potential subject who meets any of the following criteria will be excluded from
             participation in this study:

          -  Antifungal therapy was started &gt;120hours prior to BAL sampling (*)

          -  Antifungal prophylaxis with posaconazole or voriconazole for &gt;5 days within the 2
             weeks preceding BAL sampling

          -  Antifungal prophylaxis with itraconazole and at least half of the plasma
             itraconazole/hydroxy-itraconazole levels that were measured through therapeutic drug
             monitoring were above the minimum effective plasma concentration of 0.5mg/L (parental
             compound only, HLPC assay method). The minimum effective plasma concentration of
             0.5mg/L for itraconazole has been established by the ECIL 6 meeting with a
             recommendation AII.

        (*) Patients that develop new pulmonary infiltrates during antifungal prophylaxis (systemic
        azoles or aerosolized amphotericin B) can be included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bart JA Rijnders, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Internal Medicine and Infectious Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Schauwvlieghe, MD</last_name>
    <phone>+31625568885</phone>
    <email>a.schauwvlieghe@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bart Rijnders, MD/PhD</last_name>
    <email>b.rijnders@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B.J. Biemond, MD/PhD</last_name>
      <email>b.j.biemond@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Janssen</last_name>
      <email>j.janssen@vumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L.F.R. Span, MD/PhD</last_name>
      <email>l.f.r.span@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PA von dem Borne, MD/PhD</last_name>
      <email>P.A.von_dem_Borne@lumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum +</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.M.P. Demandt</last_name>
      <email>a.demandt@mumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud Medisch Universitair Centrum</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W.J.F.M. van der Velden</last_name>
      <email>Walter.vanderVelden@Radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander FA Schauwvlieghe</last_name>
      <email>a.schauwvlieghe@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Alexander Schauwvlieghe</last_name>
      <email>a.schauwvlieghe@erasmusmc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Bart JA Rijnders, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander FA Schauwvlieghe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.H.W. Bruns</last_name>
      <email>a.h.w.bruns@umcutrecht.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Verweij PE, Zhang J, Debets AJM, Meis JF, van de Veerdonk FL, Schoustra SE, Zwaan BJ, Melchers WJG. In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management. Lancet Infect Dis. 2016 Nov;16(11):e251-e260. doi: 10.1016/S1473-3099(16)30138-4. Epub 2016 Sep 13. Review.</citation>
    <PMID>27638360</PMID>
  </reference>
  <reference>
    <citation>Vermeulen E, Maertens J, De Bel A, Nulens E, Boelens J, Surmont I, Mertens A, Boel A, Lagrou K. Nationwide Surveillance of Azole Resistance in Aspergillus Diseases. Antimicrob Agents Chemother. 2015 Aug;59(8):4569-76. doi: 10.1128/AAC.00233-15. Epub 2015 May 18.</citation>
    <PMID>25987612</PMID>
  </reference>
  <reference>
    <citation>van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, Kuijper EJ, Van Tiel FH, Melchers WJ, Verweij PE. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis. 2011 Oct;17(10):1846-54. doi: 10.3201/eid1710.110226.</citation>
    <PMID>22000354</PMID>
  </reference>
  <reference>
    <citation>Chong GL, van de Sande WW, Dingemans GJ, Gaajetaan GR, Vonk AG, Hayette MP, van Tegelen DW, Simons GF, Rijnders BJ. Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J Clin Microbiol. 2015 Mar;53(3):868-74. doi: 10.1128/JCM.03216-14. Epub 2015 Jan 7.</citation>
    <PMID>25568431</PMID>
  </reference>
  <reference>
    <citation>Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles? Clin Infect Dis. 2016 Feb 1;62(3):362-8. doi: 10.1093/cid/civ885. Epub 2015 Oct 20. Review.</citation>
    <PMID>26486705</PMID>
  </reference>
  <reference>
    <citation>Mavridou E, Brüggemann RJ, Melchers WJ, Mouton JW, Verweij PE. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother. 2010 Feb;54(2):860-5. doi: 10.1128/AAC.00931-09. Epub 2009 Nov 16.</citation>
    <PMID>19917751</PMID>
  </reference>
  <reference>
    <citation>Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Brüggemann RJ, Chowdhary A, Cornely OA, Denning DW, Groll AH, Izumikawa K, Kullberg BJ, Lagrou K, Maertens J, Meis JF, Newton P, Page I, Seyedmousavi S, Sheppard DC, Viscoli C, Warris A, Donnelly JP. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat. 2015 Jul-Aug;21-22:30-40. doi: 10.1016/j.drup.2015.08.001. Epub 2015 Aug 7.</citation>
    <PMID>26282594</PMID>
  </reference>
  <reference>
    <citation>Verweij PE, Lestrade PP, Melchers WJ, Meis JF. Azole resistance surveillance in Aspergillus fumigatus: beneficial or biased? J Antimicrob Chemother. 2016 Aug;71(8):2079-82. doi: 10.1093/jac/dkw259. Review.</citation>
    <PMID>27494831</PMID>
  </reference>
  <reference>
    <citation>Chong GM, van der Beek MT, von dem Borne PA, Boelens J, Steel E, Kampinga GA, Span LF, Lagrou K, Maertens JA, Dingemans GJ, Gaajetaan GR, van Tegelen DW, Cornelissen JJ, Vonk AG, Rijnders BJ. PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay® in 201 patients with haematological disease suspected for invasive aspergillosis. J Antimicrob Chemother. 2016 Dec;71(12):3528-3535. Epub 2016 Aug 15.</citation>
    <PMID>27530755</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Bart Rijnders</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>aspergillosis</keyword>
  <keyword>mycosis</keyword>
  <keyword>neutropenia</keyword>
  <keyword>hematologic diseases</keyword>
  <keyword>AsperGenius PCR</keyword>
  <keyword>Ambisome</keyword>
  <keyword>Voriconazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

